[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wounds-and-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wounds-and-injury":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,81,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100316497","human-upper-extremity-allotransplantation-fu-protocol-100316497",false,"NCT03400345","Human Upper Extremity Allotransplantation: F\u002FU Protocol","Human Upper Extremity Allotransplantation: Transplanted Patient Follow-Up Protocol","Inclusion Criteria:\n\n* Males and females 5 or more years post-unilateral or bilateral upper limb transplantation.\n* Completes the protocol informed consent form.\n* Consents to sample collection and storage (biopsies).\n* USA citizen or equivalent.\n* Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime.\n\nExclusion Criteria:\n\n* Candidate has not received an upper extremity allotransplant.\n* Any reason the study team thinks would cause the participant to be noncompliant or would put the patient at unacceptable risk if enrolled.","ALL","18 Years","100 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Upper extremity allotransplantation is a new procedure which is becoming more common in the United States. Ongoing data collection for research purposes is vital to the long-term assessment as to the safety of the procedure and accompanying immunosuppression protocol, as well as quantifying patient outcomes and changes in quality of life. For these reasons, The Johns Hopkins Hand\u002FArm Transplantation Team is interested in enrolling transplanted patients in a follow-up protocol to continue collecting informative data to further the field of vascularized composite allotransplantation.",[25,26,27],"Amputation, Traumatic","Wounds and Injury","Hand Injuries",[29,30,31,32,33,34],"Hand Transplant","composite tissue allograft (CTA)","Vascularized Composite Allotransplantation (VCA)","Amputation","Upper Limb","Immunosuppression","RECRUITING","2026-05-07",{"date":38,"type":39},"2026-05-11","ACTUAL",{"date":41,"type":39},"2017-07-25",{"date":43,"type":21},"2036-07-30",{"name":45,"class":46},"Johns Hopkins University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100590525","phase-2-sufentanil-versus-ketamine-intranasally-in-the-management-of-severe-acute-trauma-related-pain-in-children-100590525","NCT06968546","Sufentanil Versus Ketamine Intranasally in the Management of Severe Acute Trauma-related Pain in Children.","Randomized Controlled Study Comparing Sufentanil and Ketamine Intranasally in the Management of Severe Acute Trauma-related Pain in Children.","SUF-KET-PED","Inclusion Criteria:\n\n* Children aged 6 to 17 years inclusive, under 18 years old, weighing more than 10kg, and requiring analgesia for the management of acute pain\n* Presenting with pain assessed as severe using a validated pain scale (VAS \\> 6\u002F10)\n* Acute traumatic lime injury\n* Pain caused by trauma, excluding thoracic trauma with dyspnea and abdominal pain\n* Obtaining written and signe informed consent from one of the two parents or legal guardians\n* Affiliation with a social security system\n* Hemodynamically stable\n* For post-menarche girls: negative urine pregnancy test and effective contraception, in accordance with national regulations\n\nExclusion Criteria:\n\n* Patient in a state of immediate life-threatening distress\n* Parents who don't understand and\u002For don't speak French\n* Known hypersensitivity to opiods\n* Allergy to one of the study treatments\n* History of epilepsy or known psychiatric illness\n* History of respiratory, cardiac or renal insufficiency\n* Use of serotonergic antidepressants\n* Any child with an ongoing respiratory condition (asthma, laryngitis)\n* Thoracic trauma\n* Use of opioids within the 4 hours prior to arrival in the ermergency department\n* Any child with an ongoing respiratory condition (asthma, laryngitis)\n* Thoracic trauma\n* Use of opioids within the 4 hours prior to arrival in the ermergency department\n* History of head, abdominal, or spinal trauma\n* Confirmed pregnancy\n* History of toxic substance use\n* Facial or nasal trauma\n* Whithdrawal of informed consent from the parents or legal guardian","6 Years","17 Years",{"count":59,"type":21},116,"INTERVENTIONAL",[62],"PHASE2","Pain is one of the most common reasons for children to attend emergency departments, particularly following traumatic injuries such as fractures, sprains, or contusions. Despite advances in medical care, severe acute pain in children is still sometimes inadequately treated. One important reason is that intravenous pain medication can be technically difficult, stressful, or delayed in paediatric patients.\n\nIntranasal drug administration, which involves spraying medication into the nose, offers a rapid and needle-free way to relieve pain and is increasingly used in paediatric emergency care. Two medications can be administered through this route: ketamine and sufentanil. Intranasal ketamine is already widely used in children for pain management. Sufentanil is a potent opioid analgesic commonly used in adults and in anaesthesia but has been much less studied in children when administered intranasally.\n\nThe aim of this study is to compare the effectiveness and safety of intranasal sufentanil and intranasal ketamine in children aged 6 to 17 years who present to the emergency department with severe traumatic limb pain. Both medications will be given in addition to standard care, including the routine use of an oxygen-nitrous oxide gas mixture (MEOPA), which is commonly used to reduce pain and anxiety in children.\n\nChildren who take part in the study will be randomly assigned to receive either intranasal sufentanil or intranasal ketamine. Pain levels will be assessed at regular time points after medication administration using age-appropriate pain scales. Sedation level and possible side effects will also be closely monitored for a short period following treatment.\n\nThe hypothesis of this study is that intranasal sufentanil will provide greater pain relief than intranasal ketamine 30 minutes after administration, without increasing the risk of adverse effects, when both are used alongside standard emergency care.\n\nThe results of this study are expected to improve knowledge about fast, effective, and non-invasive pain relief strategies for children in emergency settings and may help optimise future pain management protocols in paediatric emergency care.",[65,26,66,67,68,69,70],"Traumatology","Fractures Bone","Analgesia","Pain","Pain Management","Acute Pain","NOT_YET_RECRUITING","2026-01-26",{"date":74,"type":39},"2026-01-28",{"date":76,"type":21},"2026-02-05",{"date":78,"type":21},"2028-03-31",{"name":80,"class":46},"Fondation Lenval",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":57,"enrollmentInfo":90,"targetDuration":4,"studyType":60,"phases":92,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100392231","phase-3-traumatic-injury-clinical-trial-evaluating-tranexamic-acid-in-children-an-efficacy-study-100392231","NCT04387305","Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study","Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study","TIC-TOC","Inclusion Criteria:\n\n1. Less than 18 years old AND\n2. Penetrating torso trauma, blunt torso trauma, or head trauma as defined below:\n3. Penetrating Torso Trauma:\n\n   a. Penetrating trauma to the chest, abdomen, neck, or pelvis with at least one of the following:\n   * age-adjusted hypotension, or\n   * age-adjusted tachycardia despite adequate resuscitation fluids, or\n   * radiographic evidence of internal hemorrhage, or\n   * clinician suspicion of ongoing internal hemorrhage\n4. Blunt Torso Trauma:\n\n   1. Clinician suspicion of hemorrhagic blunt torso injury and at least one of the following:\n\n      * age-adjusted hypotension, or\n      * age-adjusted tachycardia despite adequate resuscitation fluids\n   2. Hemothorax on chest tube placement or imaging,\n   3. Clinical suspicion of hemorrhagic blunt torso injury and Intraperitoneal fluid on abdominal ultrasonography (Focused Assessment with Sonography in Trauma),\n   4. Intra-abdominal injury on CT with either contrast extravasation or more than trace intraperitoneal fluid,\n   5. Pelvic fracture with contrast extravasation or hematoma on abdominal\u002Fpelvic CT scan with at least one of the following:\n\n      * Age-adjusted hypotension, or\n      * Age-adjusted tachycardia.\n5. Head Trauma:\n\n   1. Initial Glasgow Coma Scale (GCS) score 3 to 13 with associated intracranial hemorrhage on cranial CT scan (enroll after cranial CT scan)\n\nExclusion Criteria:\n\n* Unable to administer study drug within 3 hours of traumatic event\n* Known pregnancy\n* Known ward of the state\n* Cardiac arrest prior to randomization\n* GCS score of 3 with bilateral unresponsive pupils\n* Isolated subarachnoid hemorrhage, epidural hematoma, or diffuse axonal injury\n* Known venous or arterial thrombosis\n* Known bleeding\u002Fclotting disorders\n* Known seizure disorders\n* Known history of severe renal impairment\n* Known allergy to TXA\n* Unknown time of injury (includes suspected non-accidental trauma)\n* Previous enrollment into the TIC-TOC trial\n* Prior TXA for current injury\n* Prior opt-out\n* Non-English and non-Spanish speaking","0 Years",{"count":91,"type":21},2000,[93],"PHASE3","Trauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and\u002For torso injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for treatment effects of TXA at different levels of fibrinolysis.",[96,26,97,98],"Brain Injuries, Traumatic","Hemorrhage","Trauma Injury",[100,101,97,102,103,104,105],"Tranexamic acid","Brain Injuries","Clinical Trial","Children","Pediatric","Trauma","2025-12-09",{"date":108,"type":39},"2025-12-15",{"date":110,"type":21},"2026-10-01",{"date":112,"type":21},"2031-03-31",{"name":114,"class":46},"Daniel Nishijima, MD, MAS",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":122,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":60,"phases":125,"briefSummary":126,"conditions":127,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100397880","phase-2-locomotor-training-with-testosterone-to-promote-bone-and-muscle-health-after-spinal-cord-injury-100397880","NCT04460872","Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","Locomotor Training With Testosterone to Promote Bone and Muscle Health","Inclusion Criteria:\n\n* Men \\>18 years of age\n* Diagnosis of an incomplete SCI involving spinal segments L1 or above or a clinically complete SCI involving spinal segments T2-L1, with upper motor neuron injury signs (i.e., spasticity, hypertonicity) for \\>60-days\n* Low serum total testosterone (\\\u003C300 ng\u002FdL), bioavailable testosterone (\\\u003C110 ng\u002FdL), or free testosterone (\\\u003C46 pg\u002FmL or \\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign or symptom that may be related to low testosterone, including: loss of body hair or reduced shaving, very small testes (\\\u003C6 mL), reduced sexual desire (libido) and activity, decreased spontaneous erections (e.g., morning erections) or erectile dysfunction, breast discomfort or gynecomastia, height loss, low-trauma fracture, or low BMD, hot flushes or sweats, decreased energy, motivation, initiative, or self-confidence, fatigue or irritability, feeling sad or blue, having a depressed mood, or having a persistent low-grade depressive disorder, poor concentration or memory, sleep disturbances or increased sleepiness, mild unexplained anemia (normochromic or normocytic), reduced muscle bulk, strength, or physical performance, Increased body fat or body mass index, any other sign or symptom commonly associated with low testosterone\n* Locomotor dysfunction, definted as self-selected walking pace ≤1.0 m\u002Fs on a 10mWT, either with or without gait devices or braces and with or without assistance, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairments, as identified by a trained observer.\n* Diagnosis of first time SCI including etiology from trauma, vascular, or orthopedic pathology\n* Medically-stable condition that is asymptomatic for conditions that will interfere with the study participation\n* Willingness to administer TRT as instructed by the study staff and to abide by study protocol\n* Documented approval from the study physician verifying medical status\n\nExclusion Criteria:\n\n* Currently participating in another research protocol that may influence study outcomes.\n* Mental state that precludes understanding the study protocol.\n* Life expectancy \\\u003C12-months.\n* History of or current congenital SCI (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Frederich's ataxis) or other degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate study procedures\n* Multiple sclerosis, amyotrophic lateral sclerosis, or other neurologic impairment or injury\n* Current prostate, breast, or other organ cancer or a history of prostate or breast cancer\n* Any other diagnosed or treated cancer within the past 24-months, with the exceptions of basal or squamous cell carcinoma of the skin that has been successfully treated\n* Serum prostate-specific antigen (PSA) \\>3.0 ng\u002FmL \\[men treated with 5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are eligible to participate if PSA values are ≤1.5 ng\u002FmL\\]\n* Prostate nodule or induration noted on digital rectal exam (DRE) during screening that tests positive for prostate cancer\n* Currently seeking fertility or expected during the duration of the study\n* Gynecomastia\n* Hematocrit (HCT) \\>49%\n* Any major cardiovascular (CV) event within the last 12-months (defined as a history of acute myocardial infarction, any cardiac revascularization procedure including angioplasty, stenting, or coronary artery bypass grafting, revascularization of the carotid or middle cerebral artery or procedures to treat critical limb ischemia, or hospitalization due to unstable angina, transient ischemic attack, stroke, or peripheral vascular disease)\n* Angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (NYHA class III or IV)\n* Poorly controlled hypertension (consistently measured systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg), while on medications\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram (ECG) findings such as left bundle branch block or marked ECG abnormalities that would preclude serial screening evaluations for occult ischemic events\n* History of unprovoked deep venous thrombosis (DVT), unprovoked pulmonary embolism, history of recurrent DVT or known thrombophilia\n* LDL cholesterol \\>160 mg\u002FdL with history of any major CV event, defined above, within the last 12-months\n* Major non-CV surgery (e.g., major abdominal or thoracic procedure) within 90-days prior to screening and\u002For a major surgery scheduled at the time of screening\n* Liver enzymes (AST or ALT) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease documented by estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Lower extremity fracture in the last 12-months (exclusion criterion for participation in LT+TRT group only)\n* Femoral neck, total hip, or lumbar spine t-score below -2.5 or distal femur BMD \\\u003C0.70 g\u002Fcm2, assessed via DEXA at screening (exclusion criterion for participation in LT+TRT group only)\n* Current anticoagulant therapy (contraindication for i.m. injections)\n* Use of any of the following pharmacologic agents in the previous 90-days: any TRT formulation, any compounded or over-the-counter androgenic hormones or androgen precursors, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or growth hormone\n* Use of anti-resorptive or bone anabolic drug therapy in the previous 180-days\n* Acute use (\\>5-days) of any opioids (e.g., oxycodone, hydrocodone, etc) or systemic glucocorticoids \\>7.5 mg\u002Fd prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) within 1-week before screening visit, except men who are taking these medications for a chronic condition and are anticipated to continue treatment for the study duration\n* Known allergy to any component of the TRT formulation (e.g., sesame oil or cottonseed oil)\n* Any other condition, therapy, lab abnormality, medical or psychiatric conditions, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive study intervention, or interfere with the person's ability to participate for the entire study duration","MALE",{"count":124,"type":21},21,[62],"This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and overground walking) in men with testosterone deficiency and walking dysfunction after incomplete or complete spinal cord injury. The investigators hypothesize that LT+TRT treatment will improve muscle size and bone mineral density in men with low T and ambulatory dysfunction after incomplete or complete SCI, along with muscle fundtion and walking recovery in men with T low and ambulatory dysfunction ater incomplete SCI.",[128,129,130,26,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146],"Spinal Cord Injury","Spinal Cord Injuries","Trauma, Nervous System","Central Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male","Spinal Cord Trauma","Injuries, Spinal Cord","Walking, Difficulty","Gait Disorders, Neurologic","Locomotion Disorder, Neurologic","Wounds and Injuries","Nervous System Diseases","Testosterone Deficiency","Androgen Deficiency","Hormone Deficiency",[148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,128],"Testosterone","Testosterone enanthate","Testosterone undecanoate","Testosterone 17 beta-cypionate","Methyltestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Muscle Strength","Muscle Mass","Bone Mineral Density","Adipose Tissue","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Magnetic Resonance Imaging","Walking","Ambulation","Locomotor","Locomotion","Treadmill","2025-05-01",{"date":181,"type":39},"2025-05-06",{"date":183,"type":39},"2021-01-31",{"date":185,"type":21},"2026-06-30",{"name":187,"class":46},"North Florida Foundation for Research and Education",2]